India, Oct. 30 -- On Friday, NurExone Biologic (NRXBF) announced laboratory results demonstrating consistent anti-inflammatory activity across three separately produced batches of its bone marrow-derived mesenchymal stromal cell exosomes, supporting its commercial supply strategy and continued development of ExoPTEN.
In laboratory testing, all three batches showed dose-dependent reductions in the inflammatory proteins IL-6 and TNF-a.
At the highest tested concentration, average levels declined by approximately 88% and 57%, respectively, compared with the LPS-stimulated control.
The findings demonstrated similar biological activity across batches, with some variability observed, particularly in TNF-a responses at intermediate concentratio...